RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014

Astrid Lièvre 1, 2, * Jean-Louis Merlin 3, 4 Jean-Christophe Sabourin 5 Pascal Artru 6 Sabine Tong 7 Lucie Libert 7 François Audhuy 8 Corinne Gicquel 8 Laurence Moureau-Zabotto 9 Roch-Anicet Ossendza 10 Pierre Laurent-Puig 11, 12 Michel Ducreux 13
* Corresponding author
1 COSS - Chemistry, Oncogenesis, Stress and Signaling
2 Département d'Hépato-gastro-entérologie [CHU Pontchaillou]
3 CRAN - Centre de Recherche en Automatique de Nancy
4 ICL - Institut de Cancérologie de Lorraine - Alexis Vautrin
5 GMFC - Génétique du cancer et des maladies neuropsychiatriques
6 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
7 NPS-12 - Régénération et croissance de l'axone = Axonal Growth and Regeneration
NPS - Neuroscience Paris Seine
8 Merck & Co. Inc
9 Institut Paoli-Calmettes
10 Département d'Hépato-gastro-entérologie [Chalons-en-Champagne]
11 MEPPOT - U1147 - Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique
12 HEGP - Hôpital Européen Georges Pompidou [APHP]
13 Oncologie digestive
Département de médecine oncologique [Gustave Roussy]
Abstract : Background: RAS (NRAS + KRAS) mutation testing is required in addition to simple KRAS testing prior to initiating anti-epidermal-growth-factor-receptor (EGFR) antibodies (MAb) as in metastatic colorectal cancer (mCRC). Aims: To assess prescription and implementation rates of RAS/KRAS mutation testing. To describe the RAS/KRAS mutation test procedure and its impact on therapeutic strategy. Patients and methods: Observational retrospective study conducted from June to September 2014 in all consecutive patients with newly diagnosed mCRC. Results:Data from 375 patients (male: 57.8%; mean age, 65.7 ± 11.7 years) were analysed. RAS/KRAS mutation testing was prescribed in 90.1% of patients (338/375). The test was prescribed within 1 month around mCRC diagnosis and prior to first-line therapy in 73.1% (242/331) and 85.4% (280/328) of patients, respectively. Time from test request to receipt of results was 24.6 ± 17.2 days. 59.7% of patients (190/318) had a mutation, mainly KRAS (47.9%; 152/317). Anti-EGFR MAb was prescribed in 90.9% of RAS-wild-type cases (60/66), consistent with the goal of genotyping-testing in this population. Conclusion: In 2014, RAS genotyping-testing in addition to KRAS testing was routinely prescribed and performed in mCRC patients in France. Time to receive results remains long and must be reduced so as to match clinical practice.
Keywords : RAS Colorectal cancer Genotyping KRAS mutations
Document type :
Journal articles
Complete list of metadatas

Cited literature [9 references]  Display  Hide  Download
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01778377
Contributor : Laurent Jonchère <>
Submitted on : Thursday, August 23, 2018 - 4:10:28 PM
Last modification on : Tuesday, August 6, 2019 - 11:26:29 AM

File

Lièvre et al_RAS mutation tes...
Files produced by the author(s)

Identifiers

Collections

UR1-UFR-SVE | BIOSIT | UNIV-RENNES | UNIV-RENNES1 | HCL | CRAN | CHLS | PAOLI_CALMETTES | MARQUIS | FNCLCC | COMUE-NORMANDIE | CRAN-BIOSIS | UNIV-LORRAINE | UNIROUEN | VAUTRIN | UNIV-PARIS-SACLAY | IGR | OSS | UNIV-PARIS5 | USPC | SORBONNE-UNIVERSITE | NPS | IBPS | NPS-12 | SU-SCIENCES

Citation

Astrid Lièvre, Jean-Louis Merlin, Jean-Christophe Sabourin, Pascal Artru, Sabine Tong, et al.. RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014. Digestive and Liver Disease, WB Saunders, 2018, 50 (5), pp.507-512. ⟨10.1016/j.dld.2017.12.029⟩. ⟨hal-01778377⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

449

Files downloads

135